Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells
SM Reincke, N von Wardenburg, MA Homeyer… - Cell, 2023 - cell.com
Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most
common autoimmune encephalitis, leading to psychosis, seizures, and autonomic …
common autoimmune encephalitis, leading to psychosis, seizures, and autonomic …
Recall of preexisting cross-reactive B cell memory after Omicron BA. 1 breakthrough infection
Understanding immune responses after severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) breakthrough infection will facilitate the development of next-generation …
(SARS-CoV-2) breakthrough infection will facilitate the development of next-generation …
Map** SARS-CoV-2 antigenic relationships and serological responses
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic,
multiple variants esca** preexisting immunity emerged, causing reinfections of previously …
multiple variants esca** preexisting immunity emerged, causing reinfections of previously …
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
B Mühlemann, SH Wilks, L Baracco, M Bekliz… - Science translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires
ongoing monitoring to judge the ability of newly arising variants to escape the immune …
ongoing monitoring to judge the ability of newly arising variants to escape the immune …
[HTML][HTML] A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2
Global research to combat the COVID-19 pandemic has led to the isolation and
characterization of thousands of human antibodies to the SARS-CoV-2 spike protein …
characterization of thousands of human antibodies to the SARS-CoV-2 spike protein …
Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants
M Korenkov, M Zehner, H Cohen-Dvashi… - Immunity, 2023 - cell.com
Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …
Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells
K Fischer, A Lulla, TY So, P Pereyra-Gerber… - Nature …, 2024 - nature.com
Monoclonal antibodies are increasingly used to prevent and treat viral infections and are
pivotal in pandemic response efforts. Antibody-secreting cells (ASCs; plasma cells and …
pivotal in pandemic response efforts. Antibody-secreting cells (ASCs; plasma cells and …
Protective neutralizing epitopes in SARS‐CoV‐2
H Liu, IA Wilson - Immunological reviews, 2022 - Wiley Online Library
The COVID‐19 pandemic has caused an unprecedented health crisis and economic burden
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …